Highlights of ACC 2024
Cardiology Update
APRIL 9, 2024
The primary superiority endpoint was clinically relevant bleeding (Bleeding Academic Research Consortium [known as BARC] types 2, 3, or 5). Patients were randomized to receive ticagrelor plus aspirin (n=1700) or ticagrelor plus placebo (n=1700) and followed for 12 months.
52 
Let's personalize your content